This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almyroudis, N. G.
Right arrow Articles by Kusne, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almyroudis, N. G.
Right arrow Articles by Kusne, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2587-2590, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00452-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents{triangledown}

Nikolaos G. Almyroudis,1 Deanna A. Sutton,2* Annette W. Fothergill,2 Michael G. Rinaldi,2,3 and Shimon Kusne4

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York,1 Fungus Testing Laboratory, Department of Pathology,2 Audie L. Murphy, South Texas Veterans Health Care System, San Antonio, Texas,3 Mayo Clinic Arizona, Phoenix, Arizona4

Received 2 April 2007/ Returned for modification 6 April 2007/ Accepted 14 April 2007

We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

* Corresponding author. Mailing address: Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-4032. Fax: (210) 567-4076. E-mail: suttond{at}uthscsa.edu

{triangledown} Published ahead of print on 23 April 2007.

Antimicrobial Agents and Chemotherapy, July 2007, p. 2587-2590, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00452-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M. M., Pastor, F. J., Calvo, E., Salas, V., Sutton, D. A., Guarro, J. (2009). Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection. Antimicrob. Agents Chemother. 53: 5022-5025 [Abstract] [Full Text]  
  • Alvarez, E., Sutton, D. A., Cano, J., Fothergill, A. W., Stchigel, A., Rinaldi, M. G., Guarro, J. (2009). Spectrum of Zygomycete Species Identified in Clinically Significant Specimens in the United States. J. Clin. Microbiol. 47: 1650-1656 [Abstract] [Full Text]  
  • Alastruey-Izquierdo, A., Castelli, M. V., Cuesta, I., Monzon, A., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2009). Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers. Antimicrob. Agents Chemother. 53: 1686-1689 [Abstract] [Full Text]  
  • Khan, Z. U., Ahmad, S., Brazda, A., Chandy, R. (2009). Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole. J. Clin. Microbiol. 47: 1244-1248 [Abstract] [Full Text]  
  • Koonce, R. C., Price, C. S., Sutton, D. A., Wickes, B. L., Montero, P. N., Morgan, S. J. (2009). Lower-Extremity Zygomycosis in a Patient with Traumatic Injuries. A Case Report. JBJS 91: 686-692 [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Rodriguez, M. M., Serena, C., Marine, M., Pastor, F. J., Guarro, J. (2008). Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52: 3786-3788 [Abstract] [Full Text]  
  • Perkhofer, S., Locher, M., Cuenca-Estrella, M., Ruchel, R., Wurzner, R., Dierich, M. P., Lass-Florl, C. (2008). Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. Antimicrob. Agents Chemother. 52: 2636-2638 [Abstract] [Full Text]  
  • Rogers, T. R. (2008). Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61: i35-i40 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»